Orlando, FL -- (SBWIRE) -- 09/25/2013 -- Hot Stock Profits provides investors and traders with valuable trading tools and content as well as micro-cap stock alerts via eMail and text messages. To Join Our Text Message Alerts Service Just Text The Word Stocks To 555888 From Your Cell Phone. Our Focus Today Is On US Airways Group, Inc.(NYSE:LCC), Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA).
US Airways Group, Inc.(NYSE:LCC) shares jumped 0.69% to $18.99. American Airlines and US Airways (LCC) Group Inc. on Sept. 24 agreed to extend the deadline for completing their $14 billion merger until at least Jan. 18 as the carriers fight a U.S. antitrust lawsuit to block the combination. The boards of American parent AMR Corp. and US Airways approved moving the deadline from the original Dec. 17 date, according to a regulatory filing today. If there is a favorable order from the court on or before Jan. 17, the companies have an additional 15 days to finish the deal.
Additionally, American Airlines (AAMRQ) and US Airways Group Inc. union leaders on Sept. 19 told the U.S. antitrust chief opposing the carriers’ proposed merger that they fear jobs will be lost if he succeeds in blocking the deal. The union officials met with William Baer, head of the Justice Department’s antitrust division, at the agency’s Washington offices today for about 45 minutes, said Laura Glading, president of the Association of Professional Flight Attendants at AMR Corp.’s American.
Are investors worried about the recent updates with LCC? Find out with a free trend analysis HERE
Teva Pharmaceutical Industries Ltd (ADR) (NYSE:TEVA) stock climbed 1.87% to $38.72. The company on Sept. 24 announced the launch of the generic equivalent to ADENOSCAN® (adenosine injection) in the United States. Teva was first to file, making the product eligible for 180 days of marketing exclusivity.
ADENOSCAN® is supplied as 20 mL and 30 mL vials and is indicated as an adjunct to thallium-201 myocardial perfusion scintigraphy in patients unable to exercise adequately.
Additionally, the company on Sept. 23 announced the U.S. District Court for the District of New Jersey has issued a favorable ruling in the Company’s patent infringement lawsuit against Mylan regarding an AZILECT® (rasagiline tablets) patent which covers methods of treating Parkinson’s disease (PD). The Court has upheld the validity of Teva’s patent. Teva anticipates the Court will enter Judgment that prevents Mylan from launching its generic version of Azilect® until Teva’s patent expires in 2017.
Is TEVA going to continue its rally or drop like a rock? Find out with a free trend analysis HERE
Join Our Mobile SMS Alerts By Texting Stocks To 555888
HotStockProfits.com continuously monitors and scans the markets for day trading and swing trading signals on NASDAQ, NYSE, AMEX, OTCBB and Pink Sheet companies for its free e-newsletter subscribers.
HotStockProfits.com is not a registered investment advisor and nothing contained in any materials should be construed as a recommendation to buy or sell securities. Investors should always conduct their own due diligence with any potential investment. Please visit HotStockProfits.com website, for complete risks and disclosures.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)